On March 14, 2018 Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), reported that Arthur Lahr, Chief Executive Officer, will present at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 10:00am EDT in Boston, MA (Press release, Kiadis, MAR 15, 2018, View Source [SID1234525132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information, please contact:

Kiadis Pharma:
Karl Hård, Head of IR & Communications
Tel. +31 611 096 298
[email protected]

Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0) 203 714 1787
[email protected]

On March 15, 2018 Nordic Nanovector ASA (OSE: NANO) reported that it will present a poster reporting the anti-tumour effect of Humalutin (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma (NHL) at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 (Press release, Nordic Nanovector, MAR 15, 2018, View Source [SID1234553509]). The meeting takes place from 14-18 April in Chicago, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The preclinical data to be presented, described in an abstract published yesterday (link), demonstrate that:

In tumour cell lines:

• The unlabelled anti-CD37 antibody (NNV003) kills tumour cells mainly through an immunological process called antibody dependent cellular cytotoxicity

• Humalutin (177Lu-NNV003) was found to inhibit tumour cell growth.

In preclinical lymphoma models:

• Humalutin has shown significant tumour uptake and demonstrated an anti-tumour effect in all three NHL models (mantle cell lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia).

Jostein Dahle, Chief Scientific Officer commented: "The data is important for Nordic Nanovector as they provide an early demonstration of the potential that Humalutin has for treating different types of NHL. These encouraging data provide further support to the planned clinical development of Humalutin, for which Nordic Nanovector expects to launch a Phase I study in NHL in the second half of 2018."

Details for the poster presentation are as follows:

Poster Title: In vitro and in vivo evaluation of the beta-emitting lutetium-177 labeled anti-CD37 antibody radionuclide conjugate 177Lu-NNV003 in DLBCL, CLL and MCL models Session Date and Time: Sunday 15 April 2018, 1:00 PM – 5:00 PM (Central Time) Location: McCormick Place South, Exhibit Hall A, Poster Section 39, Poster Board Number: 11 Session Category: Experimental and Molecular Therapeutics Session Title: Modulators of Ionizing Radiation and Other Radiotherapeutics Permanent Abstract Number: 848

The poster will be available on 15 April 2018 on the company’s website at: www.nordicnanovector.com.

On March 15, 2018 Investors are betting $94 million that Ideaya Biosciences Inc.reported that it can build on a promising new approach to cancer therapy known as synthetic lethality (Press release, Ideaya Biosciences, MAR 15, 2018, View Source [SID1234525380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recently approved medications from AstraZeneca PLC and Clovis Oncology Inc. have established the market for drugs based on synthetic lethality, the notion that tumors harbor certain pairs of genes that make them vulnerable. These cells can survive if one of the genes in the pair is mutated or inhibited. If both are mutated or inhibited, they die.

AstraZeneca’s Lynparza and Clovis’s Rubraca can treat certain cancer patients with mutated BRCA genes, which are involved in repairing damaged DNA. Because BRCA is mutated, the cancer cells rely on another enzyme to repair DNA, called Parp. Lynparza and Rubraca inhibit that enzyme.

Rubraca, approved in 2016, treats certain ovarian cancer patients. Lynparza won initial approved in 2014 in ovarian cancer and gained another approval in January, for certain breast cancer patients with mutated BRCA genes.

Last year, U.S. regulators also approved the Parp inhibitor Zejula, from Tesaro Inc., to delay cancer growth in certain patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, a rare cancer.

Ideaya aims to extend the synthetic lethality field. Its programs include a drug targeting PARG, a molecular cousin of Parp, according to co-founder and Chief Executive Yujiro Hata. The drug would treat patients who also have a loss of expression of the protein produced by the gene XRCC1, which also is involved in DNA repair. Breast cancer is the likely initial indication, Mr. Hata said.

South San Francisco, Calif.-based Ideaya intends to move two synthetic-lethality drugs and a smallmolecule immuno-oncology agent into clinical trials over this calendar year and into 2019. Other startups pursuing a synthetic-lethality approach to cancer therapy include Repare Therapeutics Inc., which gathered $68 million in Series A financing last year.

Ideaya, which disclosed a $46 million Series A round in 2016, raised this Series B round from new investors 6 Dimensions Capital, Boxer Capital of the Tavistock Group, BVF Partners, Driehaus Capital Management, GV, Nextech Invest, Perceptive Advisors and Roche Venture Fund. Prior investors 5AM Ventures, Alexandria Venture Investments, Canaan Partners, Celgene Corp. and WuXi Healthcare Ventures also participated.

Nextech Partner Thilo Schroeder and Edward Hu, founding partner of 6 Dimensions, are joining the Ideaya
board. Kanishka Pothula, managing director of BVF, GV Venture Partner Vineeta Agarwala, and Nisha Marathe, investment manager at Roche Venture Fund, are joining the board as observers.

Infinity Pharmaceuticals has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Infinity Pharmaceuticals, 2018, MAR 15, 2018, View Source [SID1234524798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 15, 2018 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, reported that it will present three posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois at McCormick Place (Press release, MabVax, MAR 15, 2018, View Source [SID1234524812]). The first poster session features MVT-1075 (177Lu-CHX-A″-DTPA-HuMab5B1), the Company’s novel fully human antibody-based radioimmunotherapy (RIT) currently being evaluated in clinical development for the treatment of pancreatic cancer and other CA19-9 positive malignancies. The second presentation will feature preclinical investigations on the novel fully human antibody targeting the Thomsen-nouveau (Tn) and the sialyl Tn (sTn) cancer antigens which are highly overexpressed on ovarian and breast cancer tissues. The third poster features the Company’s immunoPET imaging agent MVT-2163 (89Zr-DFO-HuMab5B1), as a companion diagnostic for use in pancreatic cancer and CA19-9 positive malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MabVax Therapeutics Logo (PRNewsfoto/MabVax Therapeutics Holdings, I)

Paul Maffuid, Ph.D., Executive Vice President of Research and Development of MabVax, stated, "We look forward to sharing the significant progress we have made through these clinical and preclinical studies that continue to establish our growing body of data supporting the development of MVT-1075 for the treatment of pancreatic cancer and other CA19-9 cancers, and our most advanced research program focused on the Tn and sTn cancer antigens."

Dr. Maffuid continued, "MVT-1075 potentially represents a more potent analog of our fully human HuMab-5B1 therapeutic antibody and establishing these safety and early response data bring us an important step closer in providing a much-needed treatment option for patients who have these devastating cancers. Equally important, our anti-Tn/sTn antibody program has made significant progress over the last few months and these data are the subject of partnering interest."

MabVax Abstracts and Poster Presentations

Sunday April 15, 2018 from 1:00 PM – 5:00 PM CDT:
Title: A fully human antibody binds Tn and sTn carbohydrate antigens specifically on serine residues, without need for polypeptide interaction
Session Location: Poster Section 43
Abstract Number: LB-002, Poster Board Number 2
Presenting Author: Jonah Rainey, Ph.D., Executive Director, Antibody Research MabVax Therapeutics

Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:
Title: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies
Session Location: McCormick Place South, Hall A, Poster Section 42
Abstract Number: CT140, Poster Board Number 23
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President, Research & Development MabVax Therapeutics

Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:
Title: PEGylated Hyaluronidase Increases Tumor Uptake of 89Zr-DFO-HuMab-5B1 (MVT-2163) in a CA19-9 Positive Hyaluronan-Accumulating Pancreatic Cancer Model
Session Location: McCormick Place South, Hall A, Poster Section 1
Abstract Number: 3036, Poster Board Number 9
Co-presenting Authors: Paul Maffuid, Ph.D., Executive Vice President, Research & Development and Jonah Rainey, MabVax Therapeutics Executive Director, Antibody Research MabVax Therapeutics

About MVT-1075

MVT-1075 is a radioimmunotherapy product that combines established efficacy of radiation therapy with tumor specific targeting. It has the potential to deliver a more potent HuMab-5B1 based product. MVT-1075 uses small doses of the Company’s MVT-5873 antibody, coupled to a radioisotope to target pancreatic cancer cells and kill them.

About the HuMab-Tn Antibody Targeting Tn and sTn

HuMab-Tn is a fully human antibody derived from a patient vaccinated with a pool of cancer glycans, including Tn. The antibody has been affinity-matured and demonstrates highly selective Tn/sTn glycan binding. Further, the antibody recognizes a wide array of cancers, particularly ovarian and breast including approximately 90% of triple negative breast cancers tested.

About MVT-2163

MVT-1075 is an immunoPET imaging agent product that combines the established PET imaging capabilities of 89Zr with 5B1 tumor specific targeting. It has the potential to aid in identifying the best surgical treatment options for patients with pancreatic cancer and as a potential companion diagnostic with treatment options.